Biodesix (BDSX) CAO awarded 12,000 options vesting over 4 years

Rhea-AI Filing Summary

Biodesix, Inc. reported an insider equity award to a senior executive. Chief Accounting Officer Chris Vazquez was granted stock options covering 12,000 shares of Biodesix common stock on January 2, 2026.

The options have an exercise price of $6.46 per share and expire on January 1, 2036. They vest in forty-eight equal monthly installments starting January 2, 2026, generally requiring Vazquez to remain in service through each vesting date. Following this grant, Vazquez beneficially owns 12,000 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazquez Chris

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$6.46	01/02/2026		A		12,000		(1)	01/01/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. This option vests in a series of forty-eight successive equal monthly installments measured from January 2, 2026, generally subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biodesix (BDSX) report for Chris Vazquez?

Biodesix reported that Chief Accounting Officer Chris Vazquez received a grant of 12,000 stock options on January 2, 2026, reported on a Form 4.

What are the key terms of the Biodesix CAO stock option grant?

The derivative security is Stock Options (Right to Buy) Biodesix common stock, covering 12,000 shares with an exercise price of $6.46 per share and an expiration date of January 1, 2036.

How does the Biodesix CAO option grant vest?

According to the footnote, the option vests in a series of forty-eight successive equal monthly installments starting on January 2, 2026, generally subject to the reporting person’s continued service through each vesting date.

How many Biodesix derivative securities does Chris Vazquez own after this transaction?

After the reported grant, Chris Vazquez beneficially owns 12,000 stock options directly, as shown in the Form 4 table.

Is the Biodesix CAO transaction a purchase or an option award?

The filing shows an option award, coded as transaction type A for acquisition of a derivative security, not an open-market stock purchase.

What does the Form 4 indicate about ownership form for this Biodesix option grant?

The ownership form is listed as Direct (D), with no indication that the options are held through a separate entity or indirect structure.